Acadia Pharmaceuticals traded at $14.03 this Thursday June 30th, decreasing $0.20 or 1.37 percent since the previous trading session. Looking back, over the last four weeks, Acadia Pharmaceuticals lost 13.16 percent. Over the last 12 months, its price fell by 43.38 percent. Looking ahead, we forecast Acadia Pharmaceuticals to be priced at 14.58 by the end of this quarter and at 13.43 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
14.03
Daily Change
-1.37%
Yearly
-43.38%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 5,725.00 -75.00 -1.29% -47.40%
Acadia Pharmaceuticals 14.03 -0.20 -1.37% -43.38%
ALKERMES 29.79 -0.50 -1.65% 19.64%
Alnylam Pharmaceuticals 145.85 0.42 0.29% -14.08%
Aptinyx Inc 0.56 0.002 0.38% -80.56%
Biogen 203.94 -1.29 -0.63% -41.55%
BioMarin Pharmaceutical 82.87 -1.05 -1.25% -1.24%
Bristol-Myers Squibb 77.00 -1.28 -1.64% 15.69%
Cara Therapeutics 9.13 -0.47 -4.90% -36.82%
Corcept Therapeutics 23.78 -0.96 -3.88% 5.55%
Cytokinetics 40.43 -8.31 -17.05% 92.71%
Intercept Pharmaceuticals 13.63 -0.04 -0.29% -33.41%
Incyte Corp 75.97 0.08 0.11% -9.58%
Intra Cellular Therapies 57.08 -1.23 -2.11% 34.34%
J&J 177.77 0.78 0.44% 7.12%
Eli Lilly 324.41 1.41 0.44% 40.36%
Moderna Inc 142.85 0.04 0.03% -39.24%
Marinus Pharmaceuticals 4.84 0.04 0.83% -74.12%
Neurocrine Biosciences 97.48 -0.98 -1.00% 0.02%
Pfizer 52.43 1.49 2.93% 32.53%
Prothena 27.15 0.34 1.27% -48.56%
PTC Therapeutics 40.06 -0.34 -0.84% -8.46%
Ultragenyx Pharmaceutical 59.66 -0.58 -0.96% -36.61%
Seattle Genetics 176.94 -2.12 -1.18% 11.80%
Sarepta Therapeutics 74.96 -2.11 -2.74% -4.23%
Vanda Pharmaceuticals 10.89 0.04 0.37% -48.80%
Vertex Pharmaceuticals 281.79 1.44 0.51% 39.36%

Indexes Price Day Year
USND 11029 -149.16 -1.33% -24.06%
US2000 1708 -11.38 -0.66% -26.68%

Acadia Pharmaceuticals
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).